Month: December 2020

MOUNTAIN VIEW, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (NASDAQ: IGMS) (IGM) today announced the pricing of its upsized underwritten public offering of shares of its common stock at a price to the public of $90.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase shares of its common stock at a purchase price of $89.99 per each pre-funded warrant, which represents the per share public offering price of common stock less the $0.01 per share exercise price for each such pre-funded warrant. IGM expects to receive total gross proceeds of approximately $200 million from this offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by IGM. In addition, IGM has granted the underwriters a 30-day option to purchase up to...

SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today the pricing of an underwritten public offering with expected total gross proceeds of $20.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company.The securities offered by the Company consist of (i) 14,575,000 Units, each consisting of one share of common stock (the “Common Stock”), and 0.75 Warrants (“Warrants”) to purchase one share of Common Stock at a price of $1.00 per Unit and (ii) 5,425 Units, each consisting of one share of Series C Convertible Preferred Stock (the “Preferred Stock”)...

NEW YORK and VIENNA, Austria, Dec. 08, 2020 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the pricing of an underwritten public offering of 3,400,000 shares of its common stock and 2,978 shares of its Series A convertible preferred stock (the “Offering”). The public offering price of each share of common stock is $11.75 and the public offering price of each share of Series A preferred stock is $11,750 (each share of Series A preferred stock is convertible into 1,000 shares of common stock). HOOKIPA has granted the underwriters a 30-day option to purchase up to an additional 510,000 shares of its common stock at the public offering price of the common stock, less underwriting discounts and commissions. The...

ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) — Altitude Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 26,100,000 units at a price of $10.00 per unit. The units will be listed on the Nasdaq Capital Market ( “Nasdaq”) and trade under the ticker symbol “ALTUU” beginning on December 9, 2020. Each unit consists of one share of Class A common stock and one-half of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “ALTU” and “ALTUW,” respectively.Altitude Acquisition Corp. is a blank-check company formed...

AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) — HumanCo Acquisition Corp. (the “Company”) today announced the pricing of its upsized initial public offering of 25,000,000 units at a price of $10.00 per unit. The units are expected to be listed for trading on The Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “HMCOU” beginning December 9, 2020. Each unit consists of one share of the Company’s Class A common stock and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. The Company is led by Jason H. Karp, its Executive Co-Chairman, Rohan Oza, its Co-Chairman, Ross Berman, its Chief Executive Officer, Brett Thomas, its President, and Amy Zipper, its Chief Operating Officer.The Company has also entered into a unit purchase...

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public of $37.00 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $300 million. In addition, Kura has granted the underwriters a 30-day option to purchase up to an additional 1,216,500 shares of common stock. The offering is expected to close on or about December 11, 2020, subject to customary closing conditions.SVB Leerink, Credit Suisse, Barclays and Stifel are acting...

Sorrento receives Clinical Laboratory Improvement Amendments (CLIA) license from the State of California for clinical sample testingSorrento intends to initially offer three diagnostic tests for SARS-CoV-2 infection:– RT-PCR Emergency Use Authorization (EUA)-approved test using nasal pharyngeal swab– Laboratory developed test (COVI-STIX™) using shallow nasal swab– Laboratory developed test (COVI-TRACE™) using shallow nasal swabSAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has received CLIA Licensure from the State of California that permits testing of clinical samples. The Company intends to initially focus on testing for SARS-CoV-2 infection but expects to expand to include immuno-oncology tests to support its clinical trials.Sorrento...

Guernsey, Channel Islands, Dec. 08, 2020 (GLOBE NEWSWIRE) — AP Alternative Assets, L.P. (“AAA”; Euronext Amsterdam: AAA) announces that in connection with the payment of the final liquidation dividend to AAA’s unitholders on December 9, 2020 and ahead of an application to delist the AAA units from Euronext Amsterdam, the trading in AAA’s units on Euronext Amsterdam will be suspended prior to the commencement of trading on December 9, 2020, at the request of AAA, and in consultation with Euronext Amsterdam.Reference is made to the December 4, 2020 announcement for more information on the voluntary liquidation of AAA and the delisting of the units from Euronext Amsterdam. Trading in AAA’s units is not expected to resume prior to the delisting.This press release shall not constitute an offer to sell or the solicitation of...

PHILADELPHIA, PA, Dec. 08, 2020 (GLOBE NEWSWIRE) — FinTech Acquisition Corp. V (NASDAQ:FTCVU) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced the completion of its initial public offering of 25,000,000 units at a price of $10.00 per unit, which includes 3,200,000 units issued pursuant to the exercise of the underwriters’ over-allotment option, for gross proceeds to the Company of $250,000,000. The Company’s units began trading on the Nasdaq Capital Market under the symbol “FTCVU” on December 4, 2020. Each unit issued in the offering consists of one share of the Company’s Class A common stock and one-third of one warrant, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share. Once...

PHILADELPHIA, Dec. 08, 2020 (GLOBE NEWSWIRE) — Brandywine Realty Trust (NYSE:BDN) announced today that its Board of Trustees has declared a quarterly cash dividend of $0.19 per common share and OP Unit payable on January 20, 2021 to holders of record on January 6, 2021. The quarterly dividend is equivalent to an annual rate of $0.76 per share.Conference Call and Audio WebcastWe will release our fourth quarter earnings after the market close on Tuesday, February 2, 2021, and will hold our fourth quarter conference call on Wednesday, February 3, 2021 at 9:00 a.m. Eastern. The conference call can be accessed by dialing 1-833-818-6810 and providing conference ID: 7644589. Beginning two hours after the conference call, a taped replay of the call can be accessed through Friday, February 19, 2021, by calling 1-855-859-2056 and entering...